The FDA has signed off on a Phase 2 clinical trial evaluating Altimmune’s (NASDAQ:ALT) HepTcell, a peptide-based immunotherapeutic, for the treatment of chronic hepatitis B.
It has filed clinical trial applications in Canada, Spain, Germany and the UK. The study should launch in Q4.
The company says HepTcell is designed to restore
antiviral T cell responses against the most conserved antigenic domains
of the hepatitis B virus (HBV).
https://seekingalpha.com/news/3584846-altimmune-on-go-mid-stage-study-of-heptcell-in-hepatitis-b
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.